Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262322 | 0.83 | PDE10A (0.50) | CYSLTR1CYSLTR2CYP1A2GPBAR1LMNA | |
| SCHEMBL29693804 | 0.82 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL9080506 | 0.82 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL3267444 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL2913941 | 0.81 | PDE10A (0.61) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL30879956 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL8904769 | 0.79 | PDE10A (0.48) | CYSLTR1CYSLTR2CYP1A2GPBAR1LMNA | |
| SCHEMBL4938792 | 0.79 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL13334594 | 0.78 | PDE10A (0.50) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL8906354 | 0.78 | PDE10A (0.47) | CYSLTR1CYSLTR2CYP1A2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989472-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | claimed |
| WO-2010138833-A1 | SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2010-12-02 | — | — | WO | claimed |
| CN-101528718-A | Modulators of glucocorticoid receptor and/or AP-1 and/or NF- κ B activity and uses thereof | BRISTOL MYERS SQUIBB CO (US) | 2009-09-09 | — | — | CN | claimed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | claimed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | claimed |
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | LU ZHIMIN | 2009-03-26 | — | — | US | claimed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | claimed |
| EP-2001472-A2 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck and Co., Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2007111864-A2 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-10-04 | — | — | WO | claimed |
| US-5231103-A | Lipoxygenase inhibitors as antiinflammatory agents, antiasthma and cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | claimed |
| US-5192771-A | Lipoxygenase inhibitors as antiinflammatory agents | BAYER AKTIENGESELLSCHAFT (DE) | 1993-03-09 | — | — | US | claimed |
| US-5179106-A | SUBSTITUTED N-(QUINOLIN-2-YL-METHOXY) BENZYL-SULPHONYLUREA LEUKOTRIENE SYNTHESIS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-01-12 | — | — | US | claimed |
| US-5166161-A | Antiallergens or antiinflammatory agents | PFIZER INC. (US) | 1992-11-24 | — | — | US | claimed |
| US-5126354-A | LEUKOTRIENE SYNTHESIS-INHIBITING DISUBSTITUTED (QUINOLIN-2-YL-METHOXY) PHENYLACETIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-30 | — | — | US | claimed |
| US-5109009-A | QUINOLINE AND PYRIDINE COMPOUNDS AND INHIBITION OF 5-LIPOXYGENASES THEREWITH | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-04-28 | — | — | US | claimed |
| US-5045547-A | Leukotriene-inhibiting substituted (quinolin-2-yl-methoxy)phenyl-N,N'-sulphonylureas and use thereas | BAYER AKTIENGESELLSCHAFT (DE) | 1991-09-03 | — | — | US | claimed |
| EP-0414076-A1 | Cyclic substituted (quinoline-2-yl-methoxy)phenylacetic acid derivatives | BAYER AG (DE) | 1991-02-27 | — | — | EP | claimed |
| CN-1045778-A | (quinolin-2-ylmethoxy) phenyl-N that replaces, N '-sulfonylurea, its preparation method and the application in medicine thereof | BAYER AG (DE) | 1990-10-03 | — | — | CN | claimed |
| US-4826987-A | Pyridyl and quinoline derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1989-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | RELA, NFKBIA, NFKB1 | CYSLTR1 3021/4885CYSLTR2 3514/4885CYP1A2 1668/4885 |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | CYSLTR1 530/4885CYSLTR2 306/4885CYP1A2 1996/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | CYSLTR1 385/4885CYSLTR2 712/4885CYP1A2 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.